CL2021001076A1 - Pharmaceutical composition comprising a combination of 1.3-2.5% tetrahydrocannabinol (thc) and 0.6-1.4% cannabidiol (cbd); its manufacturing process; and its use for the treatment of chronic refractory pain. - Google Patents

Pharmaceutical composition comprising a combination of 1.3-2.5% tetrahydrocannabinol (thc) and 0.6-1.4% cannabidiol (cbd); its manufacturing process; and its use for the treatment of chronic refractory pain.

Info

Publication number
CL2021001076A1
CL2021001076A1 CL2021001076A CL2021001076A CL2021001076A1 CL 2021001076 A1 CL2021001076 A1 CL 2021001076A1 CL 2021001076 A CL2021001076 A CL 2021001076A CL 2021001076 A CL2021001076 A CL 2021001076A CL 2021001076 A1 CL2021001076 A1 CL 2021001076A1
Authority
CL
Chile
Prior art keywords
cannabidiol
cbd
thc
treatment
combination
Prior art date
Application number
CL2021001076A
Other languages
Spanish (es)
Inventor
Jacqueline Ruz Miranda Patricia
Original Assignee
Knop Laboratorios S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knop Laboratorios S A filed Critical Knop Laboratorios S A
Priority to CL2021001076A priority Critical patent/CL2021001076A1/en
Publication of CL2021001076A1 publication Critical patent/CL2021001076A1/en
Priority to PE2022000670A priority patent/PE20230246A1/en
Priority to BR102022007797-5A priority patent/BR102022007797A2/en
Priority to MX2022004960A priority patent/MX2022004960A/en
Priority to CONC2022/0005205A priority patent/CO2022005205A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UNA COMBINACIÓN DE 1,3-2,5% DE TETRAHIDROCANNABINOL (THC) Y 0,6-1,4% DE CANNABIDIOL (CBD), DONDE LA COMPOSICIÓN COMPRENDE DE 10 A 25% DE INFLORESCENCIA; SU PROCESO DE ELABORACIÓN; Y SU USO PARA EL TRATAMIENTO DEL DOLOR CRÓNICO REFRACTARIO.PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMBINATION OF 1.3-2.5% OF TETRAHIDROCANNABINOL (THC) AND 0.6-1.4% OF CANNABIDIOL (CBD), WHERE THE COMPOSITION INCLUDES FROM 10 TO 25% OF INFLORESCENCE; ITS PREPARATION PROCESS; AND ITS USE FOR THE TREATMENT OF CHRONIC REFRACTORY PAIN.

CL2021001076A 2021-04-26 2021-04-26 Pharmaceutical composition comprising a combination of 1.3-2.5% tetrahydrocannabinol (thc) and 0.6-1.4% cannabidiol (cbd); its manufacturing process; and its use for the treatment of chronic refractory pain. CL2021001076A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CL2021001076A CL2021001076A1 (en) 2021-04-26 2021-04-26 Pharmaceutical composition comprising a combination of 1.3-2.5% tetrahydrocannabinol (thc) and 0.6-1.4% cannabidiol (cbd); its manufacturing process; and its use for the treatment of chronic refractory pain.
PE2022000670A PE20230246A1 (en) 2021-04-26 2022-04-22 PHARMACEUTICAL COMPOSITION BASED ON THC AND CBD FOR THE TREATMENT OF CHRONIC REFRACTORY PAIN
BR102022007797-5A BR102022007797A2 (en) 2021-04-26 2022-04-25 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CHRONIC REFRACTORY PAIN, PROCESS FOR PREPARING A PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOSITION
MX2022004960A MX2022004960A (en) 2021-04-26 2022-04-25 Pharmaceutical composition based on thc and cbd for the treatment of chronic refractory pain.
CONC2022/0005205A CO2022005205A1 (en) 2021-04-26 2022-04-26 Pharmaceutical composition based on thc and cbd for the treatment of refractory chronic pain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2021001076A CL2021001076A1 (en) 2021-04-26 2021-04-26 Pharmaceutical composition comprising a combination of 1.3-2.5% tetrahydrocannabinol (thc) and 0.6-1.4% cannabidiol (cbd); its manufacturing process; and its use for the treatment of chronic refractory pain.

Publications (1)

Publication Number Publication Date
CL2021001076A1 true CL2021001076A1 (en) 2021-09-24

Family

ID=77999519

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001076A CL2021001076A1 (en) 2021-04-26 2021-04-26 Pharmaceutical composition comprising a combination of 1.3-2.5% tetrahydrocannabinol (thc) and 0.6-1.4% cannabidiol (cbd); its manufacturing process; and its use for the treatment of chronic refractory pain.

Country Status (5)

Country Link
BR (1) BR102022007797A2 (en)
CL (1) CL2021001076A1 (en)
CO (1) CO2022005205A1 (en)
MX (1) MX2022004960A (en)
PE (1) PE20230246A1 (en)

Also Published As

Publication number Publication date
CO2022005205A1 (en) 2022-07-19
MX2022004960A (en) 2022-10-27
BR102022007797A2 (en) 2022-11-01
PE20230246A1 (en) 2023-02-07

Similar Documents

Publication Publication Date Title
MX2021008702A (en) USE OF CANNABINOIDS IN THE TREATMENT OF COMORBIDITIES ASSOCIATED WITH EPILEPSY.
MX2026002647A (en) Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
CL2020003368A1 (en) Composition and method of treating pain
CL2020000632A1 (en) Composition and method for the treatment of autism.
CO2019001895A2 (en) Novel formulation for oral administration
PE20230607A1 (en) CANNABIS COMPOSITION
PE20201163A1 (en) COMPOSITIONS AND TREATMENTS FOR SLEEP DISORDER
PA8780201A1 (en) PIRASOL DERIVATIVES REPLACED WITH HETEROARIL USEFUL TO TREAT HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
UY37952A (en) FORMULATIONS OF AN INHIBITOR OF THE QUINASA TRK MACROCYCLIC
CO2023000130A2 (en) Composition and method for the treatment of chronic pain
BR112015018095A2 (en) Spiro-lactam nmda receptor modulators and uses thereof
PE20200338A1 (en) NOVEL CANNABINOID COMPOSITIONS AND METHODS TO TREAT CHILDHOOD EPILEPSY
MX2022008478A (en) Low-dose brimonidine combinations and uses thereof.
ECSP22040921A (en) PHARMACEUTICAL COMPOSITION THAT COMPRISES SELEXIPAG
MX2015011255A (en) Flavonoid-based composition for pharmaceutical, nutritional or cosmetic use having potentiated antioxidant action.
BR112022021640A2 (en) CANNABINOIDS USES AND FORMULATIONS
MX2021013285A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex.
NI201900004A (en) VAGINAL COMPOSITION INCLUDING A COMBINATION OF ESTROGEN AND VITAMIN D.
MX2022001429A (en) FORMULATIONS THAT INCLUDE DIHYDROHONOKIOL.
PE20211198A1 (en) METHODS AND FORMULATIONS TO TREAT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
CL2021001076A1 (en) Pharmaceutical composition comprising a combination of 1.3-2.5% tetrahydrocannabinol (thc) and 0.6-1.4% cannabidiol (cbd); its manufacturing process; and its use for the treatment of chronic refractory pain.
CL2021002430A1 (en) Vaginal Tablet Formulation
MX2021008602A (en) COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF SYMPTOMS OF THE LOWER URINARY TRACT.
AR073086A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AN ANXIETY DISORDER INCLUDING EXO-7- (8-H-8-AZA-BICICLO (3,2,1) OCT-3-ILOXI) -CROMEN-2-ONA, USE AND EQUIPMENT
CL2022003426A1 (en) Levilimab Aqueous Pharmaceutical Composition and Its Use